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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S73Conclusions: Pro-inﬂammatory cytokines are elevated in SF, but not in
serum, immediately after knee ACL injury. SF TNF-a level stay elevated
over the ﬁrst 5 years after ACL injury and this high TNF- a concentration
may contribute to a later development of OA.
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MULTIPLEX ANALYSIS OF OSTEOARTHRITIC SYNOVIAL FLUID:
A COMPARISON OF LUMINEX & MESOSCALE DISCOVERY
C. Jayadev, S. Snelling, A. Price, P. Hulley. Univ. of Oxford, Oxford, United
Kingdom
Purpose: Multiplex immunoassay platforms are indispensible for
biomarker discovery. They allow high-throughput, multiple parallel
analysis of precious small volume samples. The 2 dominant technolo-
gies are Luminex (LX) and MesoScale Discovery (MSD). Neither plat-
form is validated for synovial ﬂuid (SF) analysis. The cross-comparison
of multiplex formats and comparison against the existing gold standard
of ELISA are required to facilitate quality control and guide optimum
assay selection for biomarker discovery. Previous comparison studies in
culture medium and serum/plasma cannot be extrapolated to the
complex biological matrix of SF. The aim was to make a detailed
comparison between LX and MSD platforms during the analysis of
real clinical SF samples from end-stage knee OA.
Methods: SF aliquots from patients with end-stage knee OA (N¼31)
were analysed for the inﬂammatory cytokines IL1b, TNFa, IL6 & IL8
using magnetic-bead LX and MSD multiplex assays. All SF samples
underwent identical collection, processing, storage and hyaluronidase
treatment. Aliquots of an additional SF sample were analysed by each
platform after spiking with 2 known concentrations (high & low) of the
respective assay calibrator. ELISA for IL6 & TNFa was performed on
aliquots from patients previously analysed by the LX (n¼8) and MSD
(n¼11) platforms. The LX and MSD assays were compared for limits of
detection (LOD) & quantiﬁcation (LOQ), spike recovery, and intra-assay
precision. Agreement of cytokine measurements between platforms
and against ELISA was tested by: weighted Deming Regressions (WDR),
concordance correlation coefﬁcient (CCC) for absolute agreement and
intraclass correlation coefﬁcient (ICC) for consistency. P<0.05 was
considered signiﬁcant.
Results: LOD: The MSD platform had a signiﬁcantly lower LOD for all 4
analytes (p<0.01). IL6 & IL8 were >LOD in all samples on both plat-
forms. IL1b & TNFa were >LOD in signiﬁcantly more samples on the
MSD platform: IL1b 81% vs 3% (p<0.001); TNF-a 100% vs 3% (p<0.001).
LOQ: The MSD platform had the lowest LOQ for all 4 analytes, which
was signiﬁcant for all except IL6. Both platforms were able to quantify
IL6 & IL8 in >96% of samples. IL1b & TNFa were not quantiﬁable by the
LX assay compared to 29% (p¼0.003) and 87% (p<0.001) by the MSD
assay. Spike-recovery: Spike recoveries on the MSD platform were
acceptable (10020%) for both concentrations except for the IL6 low-
spike (76.6%). IL6 & IL8 had acceptable recoveries for both spikes
concentrations on the LX platform. Recoveries at either spike concen-
trations were below acceptable for IL1b & TNFa. Intra-assay precision:
The coefﬁcient of variation (CV) for replicate measurements for all
analytes was acceptable (<20%) irrespective of platform. There was no
signiﬁcant difference in median CV between platforms. ELISA valida-
tion: All samples were <LOD on the TNFa ELISA. There was no signiﬁ-
cant systematic or proportional error for IL6 measurements by the
either platform vs ELISA (WDR). There was moderate concordance for
MSD vs ELISA (CCC¼0.901) and poor concordance for LX vs. ELISA
(CCC¼0.768) The consistency of measurements for both platforms vs
ELISA was excellent (>0.90). Cross-platform agreement: There wasTable 1
Cross-sectional ARGS-aggrecan concentrations (nM) in synovial ﬂuid (SF) and serum af
percentiles) with fold difference of the medians compared to REF. P-values, Mann-Whitn
n SF-ARGS fold dif. p-values
REF 21 0.85 (0.57, 1.30) - -
Baseline 51 6.85 (4.41,17.25) 8.1 <0.001
16 weeks 50 1.22 (1.00, 1.89) 1.4 0.005
30 weeks 48 1.10 (0.77, 1.77) 1.3 0.068
1 year 49 0.95 (0.74, 1.32) 1.1 0.349
2 years 85 1.07 (0.79, 1.28) 1.3 0.138
5 years 63 1.01 (0.69, 1.39) 1.2 0.266proportional bias but no systematic bias in IL6 & IL8 measurements
between platforms. The concordance of IL6 (CCC¼0.62) and IL8
(CCC¼0.53) measurements was poor, but the relative agreement was
excellent (ICC>0.95).
Conclusions: The MSD platform is better able to detect and quantify
low-level analytes (IL1b & TNFa) in OA SF samples than LX. There is poor
absolute agreement but excellent relative agreement between plat-
forms. This is most likely due to differences in antibody pairs and
kinetics. Cytokine measurements in OA samples are at best semi-
quantitative and depend on the platform, assay and manufacturer, thus
making comparisons between studies difﬁcult. Biomarker studies
should be consistent and explicit regarding assays.
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LONGITUDINAL CHANGE IN SYNOVIAL FLUID AND SERUM LEVELS OF
ARGS-AGGRECAN OVER 5 YEARS AFTER ANTERIOR CRUCIATE
LIGAMENT INJURY
S. Larsson y, M. Hansson y, R. Frobell y, L.S. Lohmander y,z,
A. Struglics y. yDept. of Orthopaedics, Clinical Sci. Lund, Lund Univ.,
Lund, SWEDEN; zRes. Unit for Musculoskeletal Function and
Physiotherapy, and Dept. of Orthopaedics and Traumatology, Univ. of
Southern Denmark, Odense, Denmark
Purpose: Aggrecanase cleavage at the 373Glu-374Ala bond in the
interglobular domain of aggrecan, releasing N-terminal 374ARGS frag-
ments into synovial ﬂuid (SF-ARGS), is an early key event in arthritis
and joint injuries. We have previously shown that SF-ARGS is associated
with radiographic progression of knee osteoarthritis (OA) as well as
with progression of self-reported pain after meniscectomy. As a part of
a randomized controlled study (KANON), initiated to investigate
structured rehabilitation of anterior cruciate ligament (ACL) injuries
with or without surgical reconstruction, we here report ARGS-aggrecan
levels in SF and in serum over 5 years after ACL injury.
Methods: One hundred and twenty-one subjects (26% women, mean
age 26 years, standard deviation [SD] 4.9 years) with an ACL rupture to
a previously un-injured knee were followed within 3 weeks from
trauma (baseline), at 16 weeks, 30 weeks, 1 year, 2 years and 5 years.
Blood samples were obtained from all subjects and SF was collected
from a subset of subjects (6 subjects had intact series of both SF and
serum samples). Twenty-one knee-healthy individuals (38% women,
mean age 28 years, SD 9.4 years) were used as reference. Levels of
ARGS-aggrecan were measured in all SF and serum samples with an
electrochemiluminescence immunoassay using an anti-aggrecan anti-
body (AHP0022; Invitrogen) for capture, and a monoclonal anti-ARGS
(OA-1) for detection. We used Mann-Whitney rank sum test for
comparison of ARGS-concentrations at different time points compared
to knee-healthy references, and Spearman's rank order correlation for
assessment of correlation, based on Shapiro-Wilk test indicating
skewed distributions at all time points.
Results: Levels of ARGS-aggrecan in SF and serum correlated (Spear-
man's rho¼ 0.245, p< 0.001, n¼ 356) and were overall 10 times higher
in SF than in serum: median nM ARGS in SF (25th and 75th percentiles)
in ACL injured at all time points combined 1.16 (0.83, 1.94) and 0.13
(0.10, 0.17) in serum.
SF-ARGS levels in the ACL injury group were elevated compared to
knee-healthy references at baseline and at 16 weeks after injury, but
after 30 weeks or longer, levels were not signiﬁcantly different from
those observed in the reference group (Table 1). ACL injury serum-ARGS
levels compared to knee-healthy reference level were signiﬁcantly
elevated at baseline but not at any other time point (Table 1).ter ACL injury and in knee-healthy subjects (REF). Values are medians (25th, 75th
ey rank sum tests against uninjured references.
n serum-ARGS fold dif. p-values
19 0.112 (0.075, 0.138) - -
120 0.158 (0.114, 0.198) 1.4 0.002
64 0.134 (0.099, 0.168) 1.2 0.073
63 0.137 (0.107, 0.164) 1.2 0.075
63 0.129 (0.105, 0.157) 1.2 0.148
118 0.125 (0.094, 0.153) 1.1 0.290
115 0.113 (0.091, 0.143) 1.0 0.784
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S74Longitudinal variations of SF-ARGS and serum-ARGS are presented for
the six subjects that had samples available from all visits (Figure 1).
Conclusions: Levels of ARGS-aggrecan in synovial ﬂuid are increased
compared to knee-healthy individuals over the ﬁrst 16 weeks after ACL
injury, thereafter these levels seem to normalize with levels in synovial
ﬂuid being no different from that in uninjured, knee-healthy individ-
uals. Serum levels of ARGS-aggrecan display a temporal change after
trauma, although less pronounced than in SF.Figure 1. Longitudinal change in ARGS-aggrecan concentrations in synovial ﬂuid (SF)
and serum in six subjects with a complete set of samples from all visits.121
THE ANATOMICAL SITE OF SYNOVIAL FLUID SAMPLING FROM THE
OSTEOARTHRITIC KNEE: DOES IT MATTER?
C. Jayadev, S. Snelling, P. Hulley, A. Price. Univ. of Oxford, Oxford, United
Kingdom
Purpose: End-stage anteromedial knee OA (AMOA) is associated with
limited lateral joint space narrowing osteophytosis or synovitis. Syno-
vial ﬂuid (SF) is a non-Newtonian biological ﬂuid with a complex non-
homogenous matrix. Despite the free ﬂow of SF within the knee, this
raises the possibility of compartment-speciﬁc SF biology. Equilibrium in
SF composition between knee joint compartments is assumed, but has
never been formally tested. Anatomical variations in SF analysis would
have important practical implications for the consistency of sampling
needed for biomarker research, especially for unicompartmental OA.
This study aims to determine if the anatomical site of sampling affects
SF analysis in patients with end-stage AMOA and tri-compartmental OA
(TCOA).
Methods: SF was collected from the medial, lateral and patello-femoral
(PF) compartments of patients with AMOA (n¼8) and TCOA (n¼8) at the
time of primary arthroplasty (total N¼16). Site-speciﬁc SF collection
(w250ml/compartment) was done simultaneously prior to arthrotomy.
Samples underwent identical processing, storage and preparation.
Samples were analysed for 9 pro-inﬂammatory cytokines (IL1b, TNFa,
IL6, IL8, IL15, IL2, IL12, IL17 & GMCSF), 4 regulatory cytokines (IL1RA, IL4,
IL10, IL2R), 7 chemokines (Eotaxin, IP10, MCP1, MIG, MIP1a, MIP1b,
RANTES) and TGFb1, -b2 & -b3. Each of the three joint compartments
was given a Kellgren & Lawrence grade (KLG), and the OARSI systemwas
applied to the medial and lateral compartments only as originallydescribed. Within-subject comparisons of KLG and OARSI scores for
joint space narrowing (JSN) and osteophytosis (OP) between joint
compartments were conducted separately for patients with AMOA and
TCOA. P<0.05 was considered statistically signiﬁcant. The agreement of
SF measurements between compartments was assessed for each ana-
lyte using the coefﬁcient of variation (CV) and intraclass correlation
coefﬁcient (ICC). The acceptable threshold for cross-compartment CV
(cCV) was set at 20%, which is the threshold for acceptable intra- and
inter-assay precision. An ICC >0.80 was considered excellent absolute
agreement.
Results: Compartment KLG (p<0.001), OARSI JNS (p¼0.012) and OARSI
OP (p¼0.030) scores for AMOA were signiﬁcantly higher in the medial
compartment, but there was no signiﬁcant difference between sites for
TCOA. In both AMOA and TCOA patients, only 10 analytes were quan-
tiﬁable in 75% (6/8) of compartment-matched samples to allow
meaningful analysis: 4 pro-inﬂammatory cytokines (IL6, IL8, IL12 &
IL15); 3 chemokines (Eotaxin, MCP1 & IP10); and the 3 isoforms of TGFb.
The median cCV for all analytes was <15% in both AMOA and TCOA
patient groups. The median cCV was signiﬁcantly less than 20% (one
sample Wilcoxon signed rank test) for all analytes in both patient
groups. The ICC for absolute agreement was>0.80 for all analytes in the
both patient groups. Seven (out of 10) analytes had ICCs >0.90 in both
groups.
Conclusions: There is excellent agreement between compartment-
speciﬁc SF measurements in both AMOA and TCOA. The anatomical site
of sampling does not affect SF analysis even when there are signiﬁcant
compartmental differences in structural burden of disease. The ﬁndings
strongly suggest biological equilibrium in SF composition between joint
compartments in end-stage knee OA. Consequently, the anatomical site
of SF collection is not an important practical implication for biomarker
research in knee OA.122
PROFILING OF PROTEOLYTICAL ACTIVITY INVESTIGATED BY NOVEL
MONOCLONAL ANTIBODIES AGAINST ACTIVE ADAMTS-4 AND MMP-
9 IN A BOVINE CARTILAGE EX VIVO MODEL AND IN HUMAN OA
CARTILAGE IN SITU
Y. He y, S. Sun y, Q. Zheng z, O. Simonsen x, K. Petersen k,
T. Christiansen {, M. Karsdal y, K. Henriksen y, A. Bay-Jensena y. yNordic
BioSci., Herlev, Denmark; zNordic BioSci. China, Beijing, China; xDept.
Orthopedic Surg, Aalborg Univ. Hosp., Aalborg, Denmark; k Ctr. for
Sensory-Motor Interaction, Dept. of Hlth.Sci. and Technology, Aalborg
Univ., Herlev, Denmark; {Gentofte Univ. Hosp., Hellerup, Denmark
Purpose: A disintegrin and metalloproteinase with thrombospondin
motifs 4 (ADAMTS-4, aggrecanase1) and matrix metalloproteinase 9
(MMP-9, Gelatinase B) are believed two of the main drivers in the
degradation of cartilage in osteoarthritis (OA). Both ADAMTS-4 and
MMP-9 are synthesized as latent pro-enzymes that require the removal
of the pro-domain, exposing the N-terminal neoepitope, to achieve
activity. We developed monoclonal antibodies against the neoepitopes
of active ADAMTS-4 and MMP-9 to investigate the distribution of pro-
teolytical activity in cartilage of OA patients.
Methods: We established and characterized a competitive ELISAs
for measuring the active forms of ADAMTS-4 and MMP-9 speciﬁ-
cally. Speciﬁcity of the antibodies was tested by ELISAs and western
blot, using synthetic peptides and pro- and latent puriﬁed prote-
ases. We used these assay to proﬁle proteolytical activity and their
aggrecan (AGNx-1, AGNx-2) and type II collagen degradation
products (C2M) in a bovine cartilage ex vivo model (21 days). The
location of the proteolytical activity in human OA patients (n¼20)
was investigated by immunohistochemistry using the speciﬁc
antibodies. Safranin O (proteoglycans) and fast green (collagens)
staining and scored according to modiﬁed Mankin were done on
adjacent sections.
Results: We found that after stimulation with catabolic factors, the
cartilage initially (day 3 to 10) released high levels of aggrecanase-
derived aggrecan fragments (AGNx-1) into supernatant, but subse-
quently decreased to background levels. MMP-derived aggrecan and
type II collagen fragments (AGNx-2, C2M) were released delayed (day
15 to 21) compared to AGNx-2. Whereas active ADAMTS-4 was
retained in the cartilage and released into the supernatant continu-
ously throughout the 21 days, active MMP-9 was only observed in the
second half of the culture period. Samples of human OA cartilage
affected by varying degrees of osteoarthritis stained strongly for
